Omnicell, Inc. (OMCL)

Check out top investors' recommendation for OMCL
Last closing price (N/A)
(0.00%) ? 
Last closing price is the stock price upon last market close (date specified in parenthesis).
Return to date (1m/3m/6m/12m):
N/A ? 
Return to date is the stock return for the specified period of time.
Consensus price target (1m/3m/6m/12m):
49.50
 ? 
Consensus price target is the average analyst price target for a specified period of time.
Buy/Sell Mix (1m/3m/6m/12m):
100%/0%
 ? 
Buy/sell mix the percentage mix between Buy and Sell recommendations for a given company or a research firm. Hold recommendations are excluded.
Description:
Omnicell, Inc. provides automated solutions for medication and supply management in healthcare in the United States and internationally. The company operates in two segments, Acute Care and Non-Acute Care. It offers medication use products, including OmniRx, a dispensing system that automates the management and dispensing of medications at the point of use; AnywhereRN, a software that allows nurses to remotely operate automated dispensing cabinets; Pandora Analytics, a reporting and data analytics tool; and Savvy Mobile Medication System, which provides a mobile platform for hospital information systems. The company’s medication use products also include OmniLinkRx, a prescription routing system that allows nurses and doctors to scan handwritten prescription orders for electronic delivery to pharmacists for approval and filling; WorkflowRx, an automated pharmacy storage, retrieval, and packaging system; and Anesthesia Workstation, a dispensing system for the management of anesthesia supplies and medications. It also provides medical and surgical supply products comprising Omnicell Supply Solution, which automates the management and dispensing of medical and surgical supplies at the point of use; Omnicell Open Supply Solution, which enables remote inventory management; Supply/Rx Combination Solution, which manages medications and supplies in one cabinet or group of cabinets; OptiFlex SS, a specialty module for the perioperative areas; and OptiFlex MS, a system for the management of medical and surgical supplies. In addition, the company manufactures and sells consumable medication blister cards, packaging equipment, and ancillary products to institutional pharmacies. Further, it provides customer education and training, and maintenance and support services. The company was formerly known as Omnicell Technologies, Inc. and changed its name to Omnicell, Inc. in 2001. Omnicell, Inc. was founded in 1992 and is headquartered in Mountain View, California.
Sector:
Analyst
An analyst is a professional research analyst or an Investor Wand user who issued a recommendation for a given company.
Research Firm
A Research Firm is a company that researches and rates stocks and publishes recommendations.
Signal
Signal is a recommendation issued by an analyst. Investor Wand considers two types of recommendations: BUY and SELL.
Signal Date
A signal date is a date when a BUY or SELL recommendation was issued for given security.
Initial Price
Initial Price is the first closing price for a specified company upon recommendation release. If the recommendation is issued in after-market hours, the Initial Price is the next day’s closing price (for a given symbol). In case of dividend distributions and stock splits, Initial Price is adjusted.
Price Target
A Price Target is an analyst’s projection of a company’s stock price by the end of the recommendation period. It represents the price at which the analyst would exit his or her existing position.
Closing Date
Closing Date is the expiration date of a recommendation. The validity timeframe of a professional analyst’s recommendation is 12 months. Investor Wand analysts can set their recommendation timeframe to one, three, six, or 12 months.
Return
The return on a single open recommendation is calculated as the maximum of the current return (based on the latest closing price) and the target price return, if the symbol reached the target. The return on a single closed recommendation is calculated as the maximum of the return on the closing date (at the end of recommendation timeframe) and the target price return, if the stock hit the target price. The return is adjusted for one-time events (e.g., stock splits).
Matt Hewitt Craig-Hallum Capital Buy   Jul 28, '17     52.00  Jul 28, '18  N/A 
Steven Halper Lazard Capital Markets Buy   Jul 25, '17     47.00  Jul 25, '18  N/A 
Steven Halper Lazard Capital Markets Buy   Jan 24, '17     40.00  Jan 24, '18  N/A 
Sean Wieland Piper Jaffray Buy   Oct 30, '15   27.20  42.00  Oct 30, '16  19.85% 
Steven Halper Lazard Capital Markets Buy   Oct 30, '15   27.20  35.00  Oct 30, '16  28.68% 
Steven Halper Lazard Capital Markets Buy   Sep 03, '15   33.31  40.00  Sep 03, '16  16.72% 
Steven Halper Lazard Capital Markets Buy   May 01, '15   35.13    May 01, '16  -9.31% 
Matt Hewitt Craig-Hallum Capital Buy   Apr 09, '14   29.19  33.00  Apr 09, '15  21.65% 
Steven Halper Lazard Capital Markets Buy   Oct 31, '13   23.07    Oct 31, '14  30.52% 
Sean Wieland Piper Jaffray Buy   Jun 12, '12   13.95  16.00  Jun 12, '13  37.71%